StemGen, Inc. reported earnings results for the third quarter and nine months ended March 31, 2022. For the third quarter, the company reported net loss was USD 0.185774 million compared to USD 0.098237 million a year ago.
For the nine months, sales was USD 0.02 million compared to USD 0.039 million a year ago. Net loss was USD 0.40319 million compared to USD 0.299751 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.